FSR 2021 Annual Meeting
July 9 - 11, 2021 Orlando World Center Marriott, Orlando Florida
At the 2021 EULAR congress, Brkic and colleagues presented data from people with rheumatoid arthritis (RA)treated at Norwegian rheumatology outpatient clinics between 2010 and 2019.
Due to sample size limitations, previous studies of DMARD use and COVID-19 outcomes have combined several different rheumatic diseases and medications, and investigated a single outcome- for example, the risk of hospitalization.
In recent years, significant progress has been made towards the use of high-resolution peripheral computed tomography (HR-pQCT) imaging in research, and new potential for applications in the clinic have emerged, particularly with the advent of second generation devices.
Researchers in Canada have conducted a study suggesting that the majority of patients living with long COVID (coronavirus disease) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience chronic fatigue that is at least as severe as that seen in several other clinical conditions.
In a recent study, Indian researchers from the Department of Biochemistry, University of Delhi, reviewed a possible vital coalition of FoxOs – the Forkhead Box O subfamily of protein transcription factors, with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the etiological agent of COVID-19 (coronavirus disease).
Researchers at the University of Illinois Chicago have shown that even after lung tissue has been damaged, it may be possible to reverse fibrosis and promote tissue repair through treatment with microgel-coated mesenchymal stromal cells.
A new study has been published in the journal Vaccines that deals with the present state of research on using mAbs for the treatment of the COVID-19 disease. Many clinical trials are being conducted to evaluate the efficacy and safety of several newly designed mAbs. Some of the mAbs are directed towards immune system responses, […]
Up to a third of patients taking methotrexate – a common treatment for immune mediated inflammatory conditions such as rheumatoid arthritis and psoriasis/psoriatic arthritis – failed to achieve an adequate immune response to mRNA COVID-19 vaccines in a small study accepted for publication in the journal Annals of the Rheumatic Diseases.
Hydroxychloroquine + Azithromycin therapy at a higher dose improved survival by nearly 200% in ventilated COVID patients
However, a fascinating new study posted to the medRxiv* preprint server suggests that such disappointment may have been both premature and unwarranted, based on a re-analysis of over 250 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic.
One-quarter of people who take the drug methotrexate for common immune system disorders — from rheumatoid arthritis to multiple sclerosis — mount a weaker immune response to a COVID-19 vaccine, a new study shows.